{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:15:52Z","timestamp":1783646152227,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Bei rezidivierenden Harnwegsinfektionen (rHWI) kann Nitroxolin, ein Hydroxychinolinderivat mit niedrigen Resistenzraten, zur Langzeitprophylaxe (LP) eingesetzt werden. Hierzu liegen bislang wenige Daten vor. Unter Real-World-Bedingungen sollten in einer retrospektiven, nicht-interventionellen Studie die klinische Routine einer LP mit Nitroxolin erhoben werden. Neben demografischen Daten war das Ausma\u00df der Multimorbidit\u00e4t, vorliegende Risikofaktoren f\u00fcr eine rHWI, die Art der Antibiotikatherapie der letzten akuten Episode der rHWI und die Quote der Durchbruchsinfektionen von besonderem Interesse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>Im Zeitraum April bis Oktober 2024 wurden Daten von 360\u00a0Patienten zusammengetragen, die bei 70\u00a0\u00c4rzten eine Reinfektionsprophylaxe mit Nitroxolin bei rHWI erhielten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Die Rate der Durchbruchsinfektionen lag bei 13\u202f% und wurde \u00fcberwiegend auf dem Boden einer Urinkultur ermittelt. Die dokumentierten Patienten waren zu 20\u202f% (Frauen) bzw. 47\u202f% (M\u00e4nner) als multimorbid und zu 32\u202f% (Frauen) bzw. 48\u202f% (M\u00e4nner) als geriatrisch einzustufen. 31,6\u202f% der Patienten wiesen komplizierende Faktoren f\u00fcr eine rHWI auf. Die Therapiedauer mit Nitroxolin betrug \u00fcberwiegend 3\u20136\u00a0Monate, in seltenen F\u00e4llen mehr als 2\u00a0Jahre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die hohe Zahl von Komorbidit\u00e4ten, h\u00f6heres Alter, der hohe Anteil komplizierender Faktoren wie Harntraktanomalien und die Verwendung von Antibiotika in der letzten akuten Episode, die nicht f\u00fcr die LP der rHWI vorgesehen sind, charakterisieren die vorliegende Patientengruppe als schwierig. Dennoch ergibt sich eine g\u00fcnstige Quote von Durchbruchsinfektionen von 13\u202f% unter der LP. Die am h\u00e4ufigsten genannten Gr\u00fcnde f\u00fcr die Auswahl von Nitroxolin f\u00fcr die LP waren gute Vertr\u00e4glichkeit und Wirksamkeit, die Resistenzlage sowie positive Erfahrungen des Therapeuten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00120-025-02641-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:47:33Z","timestamp":1753706853000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylaxe rezidivierender Harnwegsinfektionen mit Nitroxolin\u00a0\u2013 Real-World-Daten aus der ProNitrox-Studie","Prophylaxis of recurrent urinary tract infections by nitroxoline\u2014real-world data of the ProNitrox study"],"prefix":"10.1007","volume":"65","author":[{"given":"A.","family":"Wiedemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Strohmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Vahlensieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kirschner-Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bannowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wirz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2641_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijantimicag.2016.10.017","volume":"49","author":"Y Abouelhassan","year":"2017","unstructured":"Abouelhassan\u00a0Y, Yang\u00a0Q, Yousafd\u00a0H, Nguyen\u00a0MT, Rolfe\u00a0M, Schultz\u00a0GS, Huigens\u00a0RW (2017) Nitroxoline: a\u00a0broad-spectrum biofilm-eradicating agent against pathogenic bacteria. Int J Antimicrob Agents 49:247\u2013251","journal-title":"Int J Antimicrob Agents"},{"key":"2641_CR2","doi-asserted-by":"crossref","unstructured":"Ahmadzada A, Fuchs F, Hamprecht A (2023) Susceptibility of Aerococcus urinae and Aerococcus sanguinicola to Standard Antibiotics and to Nitroxoline. Microbiol Spectr 11:","DOI":"10.1128\/spectrum.02763-22"},{"key":"2641_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001209.pub2","author":"X Albert","year":"2004","unstructured":"Albert\u00a0X, Huertas\u00a0I, Pereiro\u00a0I, Sanf\u00e9lix\u00a0J, Gosalbes\u00a0V, Perrotta\u00a0C (2004) Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001209.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2641_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson\u00a0ME, Pompei\u00a0P, Ales\u00a0KL, MacKenzie\u00a0CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J\u00a0Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"2641_CR5","doi-asserted-by":"publisher","first-page":"e0307923","DOI":"10.1128\/spectrum.03079-23","volume":"12","author":"F Deschner","year":"2024","unstructured":"Deschner\u00a0F, Risch\u00a0T, Baier\u00a0C, Schluter\u00a0D, Herrmann\u00a0J, Muller\u00a0R (2024) Nitroxoline resistance is associated with significant fitness loss and diminishes in vivo virulence of Escherichia coli. Microbiol Spectr 12:e307923","journal-title":"Microbiol Spectr"},{"key":"2641_CR6","unstructured":"Deutsche Gesellschaft f\u00fcr Urologie e. V (2024) https:\/\/register.awmf.org\/de\/leitlinien\/detail\/043-044. Zugegriffen: 18. Jan. 2025"},{"key":"2641_CR7","doi-asserted-by":"crossref","unstructured":"Fuchs F, Aldejohann AM, Hoffmann AM, Walther G, Kurzai O, Hamprecht AG (2022) In Vitro Activity of Nitroxoline in Antifungal-Resistant Candida Species Isolated from the Urinary Tract. Antimicrob Agents Chemother 66:","DOI":"10.1128\/aac.02265-21"},{"key":"2641_CR8","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/jac\/dkac123","volume":"77","author":"F Fuchs","year":"2022","unstructured":"Fuchs\u00a0F, Becerra-Aparicio\u00a0F, Xanthopoulou\u00a0K, Seifert\u00a0H, Higgins\u00a0PG (2022) In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract. J\u00a0Antimicrob Chemother 77:1912\u20131915","journal-title":"J Antimicrob Chemother"},{"issue":"1697","key":"2641_CR9","first-page":"e7","volume":"27","author":"F Fuchs","year":"2021","unstructured":"Fuchs\u00a0F, Hof\u00a0H, Hofmann\u00a0S, Kurzai\u00a0O, Meis\u00a0JF, Hamprecht\u00a0A (2021) Antifungal activity of nitroxoline against Candida auris isolates. Clin Microbiol Infect 27(1697):e7\u2013e10","journal-title":"Clin Microbiol Infect"},{"key":"2641_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0924-8579(00)00350-2","volume":"17","author":"TM Hooton","year":"2001","unstructured":"Hooton\u00a0TM (2001) Recurrent urinary tract infecton in women. Int J Antimicrob Agents 17:259","journal-title":"Int J Antimicrob Agents"},{"key":"2641_CR11","first-page":"452","volume":"36","author":"D Karam","year":"1988","unstructured":"Karam\u00a0D, Amgar\u00a0A, Bourlioux\u00a0P (1988) Inhibition of bacterial adhesion of uropathogenic Escherichia coli strains by the urine of patients treated with nitroxoline. Pathol Biol (paris) 36:452\u2013455","journal-title":"Pathol Biol (paris)"},{"key":"2641_CR12","first-page":"339","volume":"77","author":"W Krajewski","year":"2024","unstructured":"Krajewski\u00a0W (2024) Nitroxoline: treatment and prevention of urinary tract infections from the urologist\u2019s perspective. Cent European J Urol 77:339\u2013343","journal-title":"Cent European J Urol"},{"key":"2641_CR13","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1128\/AAC.03946-14","volume":"58","author":"M Kresken","year":"2014","unstructured":"Kresken\u00a0M, Korber-Irrgang\u00a0B (2014) In vitro activity of nitroxoline against Escherichia coli urine isolates from outpatient departments in Germany. Antimicrob Agents Chemother 58:7019\u20137020","journal-title":"Antimicrob Agents Chemother"},{"key":"2641_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/MOU.0000000000000365","volume":"27","author":"J Kranz","year":"2017","unstructured":"Kranz\u00a0J, Helbig\u00a0S, Mandraka\u00a0F, Schmidt\u00a0S, Naber\u00a0KG (2017) The revival of old antibiotics for treatment of uncomplicated urinary tract infections in the era of antibiotic stewardship. Curr Opin Urol 27:127\u2013132","journal-title":"Curr Opin Urol"},{"issue":"3","key":"2641_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000487645","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz\u00a0J et\u00a0al (2018) The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int 100(3):271\u2013278","journal-title":"Urol Int"},{"key":"2641_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/neuonc\/nou139","volume":"17","author":"JJ Lazovic","year":"2015","unstructured":"Lazovic\u00a0JJ, Guo\u00a0L, Nakashima\u00a0J, Mirsadrei\u00a0L, Yong\u00a0W, Kim\u00a0HJ, Ellingson\u00a0B, Wu\u00a0H, Pope\u00a0WB (2015) Nitroxoline induces apoptosis and slows glioma growth in vivo. Neuro Oncol 17:53\u201362","journal-title":"Neuro Oncol"},{"key":"2641_CR17","first-page":"521","volume":"66","author":"A Mitrovic","year":"2019","unstructured":"Mitrovic\u00a0A, Kos\u00a0J (2019) Nitroxoline: repurposing its antimicrobial to antitumor application. Acta Biochim Pol 66:521\u2013531","journal-title":"Acta Biochim Pol"},{"key":"2641_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12879-014-0628-7","volume":"14","author":"KG Naber","year":"2014","unstructured":"Naber\u00a0KG, Niggemann\u00a0H, Stein\u00a0G, Stein\u00a0G (2014) Review of the literature and individual patients\u2019 data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. BMC Infect Dis 14:628","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2641_CR19","doi-asserted-by":"publisher","first-page":"dlac059","DOI":"10.1093\/jacamr\/dlac059","volume":"2022","author":"L Plambeck","year":"2022","unstructured":"Plambeck\u00a0L, Fuchs\u00a0F, Sattler\u00a0J, Hamprecht\u00a0A (2022) In vitro activity of mecillinam, temocillin and nitroxoline against MDR. Enterobacterales Jac Antimicrob Resist 2022(4):dlac59","journal-title":"Enterobacterales Jac Antimicrob Resist"},{"key":"2641_CR20","doi-asserted-by":"publisher","first-page":"113975","DOI":"10.1016\/j.ejmech.2021.113975","volume":"228","author":"A Proschak","year":"2022","unstructured":"Proschak\u00a0A et\u00a0al (2022) Nitroxoline and its derivatives are potent inhibitors of metallo-beta-lactamases. Eur J Med Chem 228:113975","journal-title":"Eur J Med Chem"},{"issue":"8","key":"2641_CR21","first-page":"1005","volume":"11","author":"D Repac Antic","year":"2022","unstructured":"Repac Antic\u00a0D, Parcina\u00a0M, Gobin\u00a0I, Petkovic Didovic\u00a0M (2022) Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond. Antibiot (basel) 11(8):1005","journal-title":"Antibiot (basel)"},{"issue":"68","key":"2641_CR22","first-page":"228","volume":"34","author":"D Sachse","year":"1984","unstructured":"Sachse\u00a0D (1984) Therapie chronisch-rezidivierender Harnwegsinfekte mit Nitroxolin. Therapiewoche 34(68):228\u2013230","journal-title":"Therapiewoche"},{"key":"2641_CR23","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1128\/AAC.01484-12","volume":"56","author":"SAM Klinger","year":"2012","unstructured":"Klinger\u00a0SAM (2012) The urinary antibiotic 5\u2011nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Antimicrob Agents Chemother 56:6021\u20136025","journal-title":"Antimicrob Agents Chemother"},{"key":"2641_CR24","doi-asserted-by":"publisher","first-page":"2200568","DOI":"10.2807\/1560-7917.ES.2023.28.19.2200568","volume":"28","author":"C Stoltidis-Claus","year":"2023","unstructured":"Stoltidis-Claus\u00a0C, Rosenberger\u00a0KD, Mandraka\u00a0F et\u00a0al (2023) Antimicrobial resistance of clinical Enterobacterales isolates from urine samples, Germany, 2016 to 2021. Euro Surveill 28:2200568","journal-title":"Euro Surveill"},{"key":"2641_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00120-023-02167-5","volume":"62","author":"F Wagenlehner","year":"2023","unstructured":"Wagenlehner\u00a0F, Kresken\u00a0M, Wohlfahrt\u00a0E, Bahrs\u00a0C, Grabein\u00a0B, Strohmaier\u00a0WL, Naber\u00a0KG (2023) Therapie der Zystitis mit Nitroxolin \u2013 NitroxWin. Prospektive, multizentrische, nicht-interventionelle Studie und mikrobiologische Untersuchungen zur Resistenzsituation. Urologie 62:1186\u20131192","journal-title":"Urologie"},{"key":"2641_CR26","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1021\/acs.chemrestox.9b00183","volume":"32","author":"T Van Hau","year":"2019","unstructured":"Van Hau\u00a0T, Ruankham\u00a0W, Suwanjang\u00a0W, Songtawee\u00a0N, Wongchitrat\u00a0P, Pingaew\u00a0R, Prachayasittikul\u00a0V, Prachayasittikul\u00a0S, Phopin\u00a0K (2019) Repurposing of Nitroxoline Drug for the Prevention of Neurodegeneration. Chem Res Toxicol 32:2182\u20132191","journal-title":"Chem Res Toxicol"},{"key":"2641_CR27","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.7150\/jca.47025","volume":"11","author":"N Xu","year":"2020","unstructured":"Xu\u00a0N, Lin\u00a0W, Sun\u00a0J, Sadahira\u00a0T, Xu\u00a0A, Watanabe\u00a0M, Guo\u00a0K, Araki\u00a0M, Li\u00a0G, Liu\u00a0C, Nasu\u00a0Y, Huang\u00a0P (2020) Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity. J\u00a0Cancer 11:6633\u20136641","journal-title":"J Cancer"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02641-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:46:13Z","timestamp":1768830373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2641"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02641-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"10 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Wiedemann, F.\u00a0Wagenlehner, K.\u00a0Naber, W.\u00a0Strohmaier, W.\u00a0Vahlensieck, R.\u00a0Kirschner-Hermanns, A.\u00a0Bannowsky, S.\u00a0Wirz, J.\u00a0Salem und T.\u00a0Kuru geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}